Stockscreener 앱 받기
8.97
1.21%
-0.11
전일 마감가:
$9.08
열려 있는:
$9.125
하루 거래량:
25,489
Relative Volume:
0.48
시가총액:
$190.31M
수익:
-
순이익/손실:
$-28.50M
주가수익비율:
-4.9481
EPS:
-1.8128
순현금흐름:
$-25.87M
1주 성능:
+3.58%
1개월 성능:
-10.57%
6개월 성능:
-26.89%
1년 성능:
+0.00%
1일 변동 폭
$8.95
$9.25
1주일 범위
$8.68
$9.45
52주 변동 폭
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Compare MSLE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
8.97 | 216.09M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-06 | 개시 | Leerink Partners | Outperform |
| 2026-03-11 | 개시 | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc 주식(MSLE)의 최신 뉴스
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Why Satellos Bioscience Inc. stock is gaining today - wealthawesome.com
Satellos Bioscience (MSLE) Institutional Ownership 2026 - MarketBeat
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk - kalkine.ca
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE) - MarketBeat
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Satellos Bioscience Inc. MSCL Earnings Miss Estimates by 37.0% - Wealth Awesome
Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M - Streetwise Reports
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility - TipRanks
Satellos Bioscience (MSLE) enters $50M at-the-market share deal - Stock Titan
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside - TradingView
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.92, Implies 123% Upside - TradingView
Oppenheimer Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Satellos Bioscience: Q2 Earnings Snapshot - aol.com
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base - TipRanks
Satellos Q2 loss widens to $11.7M, EPS misses estimates - scanx.trade
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - The Manila Times
Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash - Stock Titan
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Satellos reports stable strength in four-adult Duchenne study - Stock Titan
Satellos Bioscience Files For Mixed Shelf Of Up To $300 Million - TradingView
Satellos Bioscience (MSLE) sets up US$300M shelf to fund Duchenne drug - Stock Titan
Satellos Bioscience (MSLE) Holds Ground Near $10.01 as Key Support Level Comes into FocusZero Lag EMA - vinanet.vn
Satellos Bioscience Inc. (TSX:MSCL) Stock Declines as Biotech Risks and Funding Concerns Pressure Sentiment - kalkine.ca
Satellos Bioscience (TSX:MSCL): Can This Toronto Biotech Actually Regrow Muscle in Duchenne Patients? - kalkine.ca
Satellos Bioscience Stock Climbs as Duchenne Therapy Data Strengthen Bullish Momentum: Can TSX:MSCL Extend Its Recovery? - kalkine.ca
Satellos Wins FDA Fast Track for SAT-3247 as Its Duchenne Programme Enters a Catalyst-Rich Second Half - kalkine.ca
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
Satellos Bioscience Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Faces Crucial Smallcap Tests - Kalkine Media
Satellos Bioscience Ord Shs (MSLE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Satellos Bioscience Ord Shs (MSLE) Institutional Confidence - TradingKey
Satellos Bioscience Inc Revenue Breakdown – LSX:A4211W - TradingView
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
What's Going On With Satellos Bioscience Inc. Stock Wednesday? - Wealth Awesome
Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
Independent Director of Satellos Bioscience Picks Up 1.9% More Stock - simplywall.st
MSLE Q1 2026 Earnings: EPS Misses Estimates as Development‑Stage Company Advances PipelineProduct Revenue Analysis - Vinanet
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Spending; Stock Rises Despite EPS MissGross Profit Margin - dars.gov.et
What's Going On With Satellos Bioscience Inc. Stock Thursday? - Wealth Awesome
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: EPS Misses Estimates as Development Costs ContinueEarnings Beat Alert - dars.gov.et
What is HC Wainwright's Forecast for MSLE FY2029 Earnings? - MarketBeat
Price to book forward of Satellos Bioscience Inc – SWB:0IT - TradingView
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos Bioscience (MSLE) Extends Gains: Shares Up 3.71% as Resistance at $10.28 LoomsPut Call Ratio - dars.gov.et
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports
Biotech With Muscle Disease Drug Uncovers Results in Trial Data - Streetwise Reports
Satellos Bioscience Inc (MSLE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):